PRODUCTS
PRODUCTS
APIs and intermediates
PRODUCTS
Baricitinib Intermediates
PRODUCTS
Crisaborole API & Intermedia… Topiroxostat API & Intermedi… Tavaborole API & Intermedia… Upadacitinib API & Intermed… BrexpiprazoleAPI & Intermedi… TEST Others Ticagrelor Intermediates Others Parecoxib sodium Intermediat… Canagliflozin Intermediates Empagliflozin Intermediates Dapagliflozin Intermediates Tofacitinib Intermediates Baricitinib Intermediates Baricitinib Intermediates Vonoprazan Fumarate Intermed… Febuxostat Intermediates Ceftaroline fosamil Interme… Rivaroxaban Intermediates Avatrombopag Intermediates Ramelteon Intermediates Pimavanserin Intermediates Intermediates of Carbapenems… Dabigatran etexilate Interme… Crisaborole Intermediates Finafloxacin Hydrochloride I… Meropenem Sacubitril Apixaban Intermediates Zolpidem tartrater Intermedi… Tolvaptan Intermediates Edoxaban Intermediates Nucleus and intermediates of… Acotiamide intermediates Apremilast intermediates Roxadustat intermediates Linagliptin intermediates Ibrutinib Intermediates Eltrombopag Intermediates Posaconazole Intermediates Name | trimethyl-[2-[[4-(1H-pyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl]silane |
Purity | ≥99% |
Appearance | - |
| Synonym | Baricitinib Intermediates |
| Cas No. | 941685-27-4 |
| Molecular Formula | C15H21N5OSi |
| Molecular Weight | 235.28 |
| Structural Formula |  |
| Product Introduction | trimethyl-[2-[[4-(1H-pyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl]silane [941685-27-4] Baricitinib Intermediates |
| Product Status | trimethyl-[2-[[4-(1H-pyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl]silane [941685-27-4] Our company has commercialized this product for long-term stable supply. |
| Contact Information | If you are interested in trimethyl-[2-[[4-(1H-pyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl]silane [941685-27-4],we will provide you with reasonable price, high quality products, looking forward to your contact. |
Copyright Bayeebio Biotech (Shanghai) Co., Ltd. Shanghai 滬ICP備16015574號
